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Human bone marrow transplants performed as therapeutical treatment of severe
aplastic anaemia, leukaemia and immune deficiency disease became available in the
seventies (Bortin, 1970). In an artificial Situation, such as organ transplantation, the
major Histocompatibility (H) antigens function as a major transplantation barrier and
thus play an important role in the survival of transplants and patients. Consequently,
improved success in bone marrow transplantation was reported when matching for
the HLA antigens was taken into account (Thomas, 1975). Between 1975 and the
present day, the long-term results of allogeneic bone marrow transplantation (BMT)
have greatly improved due to the use of HLA-matched siblings as marrow donors,
advanced pretransplant chemoradiotherapy, the use of potent immunsuppressive
drugs as Graft-versus-Host-Disease (GvHD) prophylaxis, better antibiotics and Isolation
procedures.
The results of clmical bone marrow (BM) transplantation reveal however that the
selection of MHC identical donors/recipients is not a guarantee of avoidance of GvHD
or disease free survival even when donor and recipient are closely related (Bortin,
1991). It is believed that disparities for minor Histocompatibility antigens (mHag)
between donor and recipient constitute a potential risk for GvHD or graft failure
(Martin, 1991; Beatty, 1989).
In man, the efforts of several investigators have led to the Identification of a small
number of mHag (Goulmy, 1977,1983; Zier, 1983; Irle, 1990; Van Eis, 1992). Here, we
will briefly focuss on their possible clinical relevance for BM transplantation in both the
GvHD and the Graft-versus-Leukemia (GvL) reactivities. Furthermore, we provide
preliminary evidence for the evolutionary conservation of human mHag.
Clinical relevance of anti-host cytotoxic Τ cells (CTLs) and helper Τ cells (Th) in the
development of GvHD
Several reports demonstrated the presence of anti-host mHag specific CTL in patients
suffering from GvHD after HLA genotypically identical BMT (Goulmy, 1983; Tsoi, 1980,
1983; Irl6,1985; Van Eis, 1990; Irscheck, 1992; Niederwieser, 1993). In our laboratory,
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much effort was put into the further characterization of a (small) number of anti-host
mHag specific CTLs. Hereto, CTL ebnes speeifie for host mHag were isolated from
the peripheral blood (PBL) of patients suffering from severe GvHD. Subsequent
immunogenetic analyses revealed that these CTL clones identified five non-sexlinked
mHag, designated HA-1, -2, -3, -4, -5, which are recognized in a classical MHC
restricted fashion (Van Eis, 1992). mHag HA-3 is recognized in the presence of HLA-
A1 and mHag HA-1, -2, -4 and 5 require the presence of HLA-A2. In order to
document the effect of mH antigens in genotypically identical BMT on the oecurrence
of acute (grade > 2) GvHD, we prospectively collected PBL from HLA-A1 and HLA-A2
positive patient/donor sibling pairs. This multi center study comprised 148 HLA
genotypically identical BM donor/reeipient combinations, adults as well as children,
grafted between 1982 and 1990. The results of the mHag typing using the CTL clones
specific for five well defined mHag HA-1 to HA-5 demonstrated (table 1) a significant
correlation between mHag HA-1, -2, -4 and -5 mismatch and GvHD (Goulmy, 1994).
Table 1 Correlation of mHaq HA-1. -2, -4 and -5. with the oecurrence of GvHD
All patients
GvHD
mHaq
match mismatch
No 41 1
Yes 40 12
Ρ = 0.002
The last few years evidence has aecumulated that in addition to CTLs mH antigen
specific helper Τ cells (Th) could be relevant in the pathogenesis of GvHD. In vitro
studies reporting on host directed Th cells have been described in patients having
GvHD (Tsoi, 1980; Reinsmoen, 1984; Irin, 1987). Van Eis et al. reported on the long
term kinetics of Th cells in response to host mH antigens in 16 patients and
demonstrated that significant Th cell activity in vitro correlates with clinical acute GvHD
(Van Eis, 1990b). In a subsequent study, we demonstrated that these anti-host Th
cells carry the CD4 phenotype and recognize mH antigens in the context of HLA-DR
and -DP (Van Eis, 1990c).
Most recent observations support the notion that mH antigen specific Th cells are by
and large likely to play a role in the pathogenesis of acute GvHD (Theobald, 1992;
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Possible involement of mHag in Graft versus Leukemia
The hypothesis that posttransplantation of bone marrow anti-host CTL activity may
have a beneficial effect is based on the assumption of the postulated anti-leukaemic
Potential as a 'desired' side-effect of the post BMT complication GvH. (Bortin, 1973;
Weiden, 1981 a, 1981 b). In search for anti-host CTL and Th cell activities post BMT, we
observed earlier both absence and presence of anti-host CTL in patients without any
clinical signs of GvHD (see table 2).
Table 2 Anti-host Τ cell activities after HLA identical BMT.
Anti-host
Th
no GvHD
acute GvHD
chronic GvHD
+ + Η
5
6
15
Anti-host
CTLs
h
4
3
1
2
6
5
5
0
2
Ν = 34 Ν = 20
It was notable that in 3 out of 4 cases without anti-host CTL activity (see table 2),
leukemia relapse was manifested. On the other hand, the presence of anti-host CTLs
in the absence of GvHD (N-5) argues for the possible role of these CTLs in the anti-
leukemic activity. In an attempt to study the post BMT anti-host CTL responses for
their putative anti-leukemic activity in vitro, we observed "GvHD" related and "GvL"
related acitivities. The latter type of CTL clones recognized patient's neoplastic cells
only. The former type of CTL clones were reactive with ligands, like mH antigens,
shared by host PBL and leukemic cells (Van Lochern, 1992). Another line of
investigation support the notion that anti-host mHag specific CTL may play a role in
the anti-leukemic effect of allogeneic BMT. Namely, mHag specific CTLs are capable
of inhibiting in vitro outgrowth of clonogeneic leukemic precursor cells as well as lyse
freshly obtained myeloid and lymphoid leukemic cells (Fakenburg, 1991; Van der
Harst, 1994).
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Human mHag are conserved in evolution
To substantiate the importance of the human mH antigenic Systems, we investigated
whether the mHag are conserved in evolution between man and chimpansee. Hereto,
cells from chimpansees were transfected with the human HLA-A2.1 gene. Subsequent
analyses with our human allo HLA-A2.1 and four mHag HLA-A2.1 restricted CTL
clones revealed the presentation of chimpansees' allo and mHag peptides in the
context of the transfected human HLA-A2.1 molecule by chimpansees' target cells
(table 3). These results implicate that the chimpansee cell derived allo and mHag
peptides investiged in this study are very similar to the human allo HLA-A2 and HLA-
A2 restricted mHag peptides.
Table 3 Human mHaq are evolutionary conserved
Human CTL clones
A2HA-1
Theo
Japie
Pearl
Debbie ¥
Gwen ¥
Brigitte ¥
Sherry ¥
76°
48
37
42
23
31
52
79
58
2
1
0
0
2
69
45
35
37
38
23
58
75
54
40
48
32
20
55
3
0
2
1
1
0
3
* chimp. target cells have been electroporated with the HLA-A2 gene.
° % specific cytotoxicity measured in a cell mediated lympholysis assay.
In conclusion, although lots of Information was gathered during the past decades on
the murine and human mHag, still many questions remain to be answered. Besides
Identification of the mHag and the genes they are encoded by, we must be able to
dissect the majors from the minor minors. To achieve this, more Information is needed
on the Th and CTL defined human mHag repertoire, and to establish the
immunodominant ones. To understand their biological role in bone marrow
transplantation Information on their cytokine secretion profile is essential.
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